Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron VariantAccesswire • 03/11/22
Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19Accesswire • 03/09/22
Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 'TRAVERS' Clinical Trial of AM-125 for the Treatment of Acute VertigoAccesswire • 02/14/22
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional MarketsAccesswire • 02/09/22
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf CountriesAccesswire • 02/07/22
Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual ConferenceAccesswire • 01/05/22
Altamira Therapeutics Announces Randomization of First Patients in Bentrio Trial in House Dust Mite AllergyAccesswire • 12/16/21
Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic RhinitisAccesswire • 12/01/21
Altamira Therapeutics Announces Poster Presentations at AHA Scientific Sessions 2021Accesswire • 11/15/21
CYTO Stock: The Nasal Spray News Blowing Altamira Therapeutics Sky-High TodayInvestorPlace • 11/12/21
Altamira Therapeutics Reports Positive In vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Delta VariantAccesswire • 11/12/21
Altamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma ConferenceAccesswire • 10/06/21